The insulin-like growth factor-1 elevates urokinase-type plasminogen activator-1 in human breast cancer cells: A new avenue for breast cancer therapy

Molecular Carcinogenesis

Volumn 27, Issue 1, 2000, Pages 10-17

  Dunn, S E ^a   Torres, J V ^a   Nihei, N ^a   Barrett, J C ^a,b  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Breast cancer; Insulin like growth factor 1; Metastasis; Urokinase type plasminogen activator 1

Indexed keywords

MATRIX METALLOPROTEINASE; MESSENGER RNA; PLASMINOGEN ACTIVATOR; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; UROKINASE;

ANGIOGENESIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER INVASION; CANCER SURVIVAL; ENZYME ACTIVITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR RECURRENCE;

BLOTTING, NORTHERN; BREAST NEOPLASMS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INSULIN-LIKE GROWTH FACTOR I; KINETICS; NEOPLASM INVASIVENESS; RNA, MESSENGER; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED; URINARY PLASMINOGEN ACTIVATOR;

EID: 0033951758     PISSN: 08991987     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2744(200001)27:1<10::AID-MC3>3.0.CO;2-Z     Document Type: Article

References (33)

1. tandis SH, Murray T, Bolden S, Wingo PA, Cancer statistics, 1999. CA Cancer J Clin 1999;49:8-31.
2. Turner BC, Haffty BG, Narayanan L, et al. Insulin-like growth factor-1 receptor overexpression mediates cellular radio-resistance and local breast cancer recurrence after lumpectomy and radiation. Cancer Res 1997;57:3079-3083.
3. Janicke F, Schmitt M, Ulm K, Gossner W, Graeff H. Urokinase-type plasminogen activator antigen and early relapse in breast cancer. Lancet 1989;28:1049.
4. Osborne CK, Clemmons DR, Arteaga CL. Regulation of breast cancer growth by insulin-like growth factors. J Steroid Biochem Mol Biol 1990;37:805-809.
5. Dunn SE, Hardman R, Kari FW, Barren JC. Insulin-like growth factor-1 alters drug sensitivity of human breast cancer cells by inhibition of apoptosis induced by diverse anticancer drugs. Cancer Res 1997;57:2687-2693.
6. Dunn SE, Ehrlich M, Sharp NJH, et al. A dominant negative mutant of the insulin-like growth factor-1 receptor inhibits the adhesion, invasion, and metastasis of breast cancer. Cancer Res 1998;58:3353-3361.
7. Doerr ME, Jones JI. The roles of integrins and extracellular matrix proteins in the insulin-like growth factor-1 stimulated chemotaxis of human breast cancer cells. J Biol Chem 1996;271:2443-2447.
8. Holst-Hansen C, Johannessen B, Hoyer-Hansen G, Romer J, Ellis V, Brunner N. Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness. Clin Exp Metastasis 1996;14: 297-307.
9. Min HY, Doyle Lv, Vitt CR, Zandonella cL, Stratton-Thomas JR, Shuman MA, Rosenberg S. Urokinase receptor antagonist inhibit angiogenesis and primary tumor growth in syngeneic mice. Cancer Res 1996;56:2428-2433.
10. Railo MJ, Smitten KV, Pekonen F. The prognostic value of insulin-like growth factor-1 in breast cancer patients. Results of a follow-up study on 126 patients. Eur J Cancer 1994;30A:307-311.
11. Resnik JL, Reischart DB, Huey K, Webster NJG, Seely BL. Elevated insulin-like growth factor 1 receptor autophosphorylation and kinase activity in human breast cancer. Cancer Res 1998;58:1159-1164.
12. Rasmussen AA, Cullen KJ. Paracrine/autocrine regulation of breast cancer by the insulin-like growth factors. Breast Cancer Res Treat 1998;47:219-233.
13. Peyrat JP, Bonneterre J, Hecquet B, et al. Plasma insulin-like growth factor-1 (IGF-1) concentrations in human breast cancer. Eur J Cancer 1993;29A:492-497.
14. Hankinson SE, Willett WC, Coldita GA, et al. Circulating insulin-like growth factor-1 and the risk of breast cancer. Lancet 1998;351:1393-1396.
15. Dunn SE, Kari FW, French J, et al. Dietary restriction reduces insulin-like growth factor-1 levels which modulates apoptosis, cell proliferation, and tumor progression in p53 deficient mice. Cancer Res 1997;57:4667-4672.
16. Ng EH, Ji CY, Tan PH, Lin v, Soo KC, Lee KO. Altered serum levels of insulin-like growth factor binding proteins in breast cancer patients. Ann Surg Oncol 1998;5:194-201.
17. Borden P, Heller RA. Transcriptional control of matrix metalloproteinases and the tissue inhibitors of matrix metalloproteinases. Crit Rev Euk Gene Exp 1997;7:159-178.
18. Watabe T, Yoshida K, Shindoh M, et al. The ETS-1 and ETS-2 transcription factors activate the promoters for invasion-associated urokinase and collagenase genes in response to epidermal growth factor. Int J Cancer 1998;77: 128-137.
19. Nihei N, Icnikawa T, Kawana Y, et al. Mapping of metastasis suppressor gene(s) for rat prostate cancer on the short arm of human chromosome 8 by irradiated microcell-mediated chromosome transfer. Genes Chromosome Cancer 1996;17:260-268.
20. Constantini V, Sidoni A, Deveglia R, et al. Combined over-expression of urokinase, urokinase receptor and plasminogen activator inhibitor-1 is associated with breast cancer progression. Cancer 1996;77:1079-1088.
21. Guerra FK, Eijan A, Puricelli L, et al. Varying patterns of expression of insulin-like growth factor I and II and their receptors in murine mammary adenocarcinomas of different metastasizing ability. Int J Cancer 1996;65: 812-820.
22. Bugge TH, Lund LR, Kombrinck KK, et al. Reduced metastasis of polyoma virus middle T antigen-induced mammary cancer in plasminogen-deficient mice. Oncogene 1998;16: 3097-3104.
23. Akagi Y, Liu W, Zebrowski B, Xie K, Ellis LM. Regulation of vascular endothelial growth factor expression in human colon cancer by insulin-like growth factor-1. Cancer Res 1998;58:4008-4014.
24. Mandriota SJ, Seghezzi G, Vassalli JD, et al. Vascular endothelial growth factor increases urokinase receptor expression in vascular endothelial cells. J Biol Chem 1995;28: 9709-9716.
25. Hildenbrand R, Dilger I, Horlin A, Stutte HJ. Urokinase plasminogen activator induces angiogenesis and tumor vessel invasion in breast cancer. Pathol Res Pract 1995;191: 403-409.
26. Coppola D, Ferber A, Miura M, et al. A functional insulin-like growth factor 1 receptor is required for the mitogenic and transforming activities of the epidermal growth factor receptor. Mol Cell Biol 1994;14: 4588-4595.
27. Fan WH, Lu YL, Deng XM, Liu S, Tang PH. EGFR antisense RNA blocks expression of the epidermal growth factor receptor and partially reverse the malignant phenotype of human breast cancer MDA-MD-231 cells. Cancer Res 1998;58:63-71.
28. Xing R, Mazar A, Henkin J, Rabbani SA. Prevention of breast cancer growth, invasion and metastasis by antiestrogen Tamoxifen alone or in combination with urokinase inhibitor B-428. Cancer Res 1997;57:3585-3593.
29. Pollak M, Constantino J, Polychronakos C, et al. Effect of tamoxifen on serum insulin like growth factor 1 levels in stage I breast cancer patients. J Natl Cancer Inst 1990;82: 1693-1697.
30. Abidi SM, Howard EW, Dmytryk JJ, Pento JT. The influence of antiestrogens on the release of plasminogen activator (uPA) by MDA-MB-231 and MCF-7 breast cancer cells. Clin Exp Metastasis 1998;16:235-241.
31. Fisher B, Constantino JP, Wickerham L, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 1998;90:1371-1388.
32. Clark R, Thompson EW, Leonessa F, Lippman J, McGarvey M, Frandsen TL, Brunner N. Hormone resistance, invasiveness and metastatic potential in breast cancer. Breast Cancer Res Treat 1993;24:227-239.
33. Alonso DF, Farina HG, Skilton G, Gabri MR, De Lorenzo MS, Gomez DE. Reduction of mouse mammary tumor formation and metastasis by lovastatin, an inhibitor of the mevalonate pathway of cholesterol synthesis. Breast Cancer Res Treat 1998;50:83-93.